Drug intelligence / Profile preview

Theraphage COVID-19 intranasal UVLP vaccine

Development stage
Preclinical
Lead developer
Theraphage
Modality
Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Intranasal
01

Overview

The Theraphage COVID-19 intranasal UVLP vaccine is a preclinical vaccine candidate developed by the Theraphage research laboratory at the University of Waterloo. This vaccine utilizes a Universal Virus-Like Particle (UVLP) platform, engineered using bacteriophage-based technology (iPhAGE system). It is designed for intranasal administration to specifically elicit both mucosal immunity in the respiratory tract and systemic immunity against SARS-CoV-2. By mimicking the structural characteristics of the virus without containing infectious genetic material, the UVLP aims to provide a robust and targeted immune response.

Other names
intranasal UVLP vaccineCOVID-19 vaccine (intranasal UVLP)
02

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on Theraphage COVID-19 intranasal UVLP vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theraphage COVID-19 intranasal UVLP vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call